Stock Ratings / Health Care / PRVA / forecast

AVAH (65) ADUS (69) WGS (58) OPCH (75) ⌘ Pro Terminal →

Privia Health Group Inc. (PRVA) 12-Month Stock Forecast & Price Target Cone

$22.00 +0.71% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Privia Health Group Inc. (PRVA) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $2.81B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-0.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PRVA)Realized 20D OHLCV Swing Band: ±6%

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your PRVA Position Size: $10,000

Shares at $22.00: 454.5 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $17.08

$7,764

$-2,236 (-22.4%)

12M Consensus BaseTarget $21.90

$9,955

$-45 (-0.5%)

12M Bull Case BreakoutTarget $30.26

$13,755

+$3,755 (+37.5%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (32 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 6

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$23	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$28	69%	B
JP MorganUS Large-Cap Research	SELL	$19	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRVA)

✓Walkthrough of PRVA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PRVA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -11.47%⚡ TESTING RESISTANCE

2026-10-30O $22.10H $22.10L $21.30C $22.00VOL 841.2K

RES: $22.54SUP: $18.32SMA50: $20.88SMA200: $22.67

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PRVA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PRVA Butterfly Map → + Track PRVA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

48.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PRVA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PRVA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PRVA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRVA)

Health Care Rank #250 of 1016 ⚔️ AVAH vs PRVA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PRVA vs. AVAH, ADUS, WGS, OPCH)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Privia Health Group Inc. (PRVA) ranks #250 by composite RQD confidence (57/100, grade D+) and #214 by equity capitalization ($2.81B). Within this direct 5-issuer industry benchmark cohort, OPCH leads on earnings valuation at 23.0x trailing P/E, while AVAH leads on capital efficiency and profitability with 15.7% ROIC and 33.3% gross margin. OPCH currently holds the highest overall quantitative score in the immediate peer group at 75/100 (B) compared with PRVA at 57/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PRVA ACTIVE Privia Health Group Inc.	D+	57/100	122.6x	—	10.5%	+0.71%	$2.81B	Benchmark Subject
AVAH Aveanna Healthcare Holdings Inc.	C	65/100	—	33.3%	15.7%	+1.53%	$2.89B	/avah-vs-prva →
ADUS Addus HomeCare Corporation	C+	69/100	24.2x	32.5%	9.1%	+1.77%	$2.32B	/adus-vs-prva →
WGS GeneDx Holdings Corp. (Class A)	D+	58/100	—	69.7%	-4.1%	+9.79%	$2.12B	/wgs-vs-prva →
OPCH Option Care Health Inc.	B	75/100	23.0x	19.3%	11.9%	+1.79%	$4.77B	/opch-vs-prva →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001759655

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Privia Health Group Inc. (PRVA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $22.9M, operating cash flow of $163.4M, and free cash flow of $163.4M (+49.5% YoY). On the balance sheet, PRVA closed FY2025 with $1.37B in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$22.9M	$163.4M	$163.4M	$1.37B	—
FY2024 (FY)	2024-12-31	$0	$14.4M	$109.3M	$109.3M	$1.14B	—
FY2023 (FY)	2023-12-31	$0	$23.1M	$80.8M	$80.8M	—	—

3. PRVA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PRVA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Privia Health Group Inc. (NASDAQ: PRVA) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $22.00 (+0.71% 1D, market cap $2.81B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 10/20. Across 1016 tracked Health Care issuers, PRVA ranks #250 in composite RQD confidence.

How does PRVA compare to AVAH and ADUS in the Health Care sector?

Within the Health Care sector (Medical/Nursing Services), PRVA carries a Roarable D+ (57/100 RQD), trailing P/E of 122.6x, gross margin of —, and ROIC of 10.5%. By comparison, AVAH (Aveanna Healthcare Holdings Inc.) holds a C grade (65/100 RQD, P/E N/A, ROIC 15.7%, cap $2.89B) and ADUS (Addus HomeCare Corporation) posts a C+ grade (69/100 RQD, P/E 24.2x, ROIC 9.1%, cap $2.32B). Among the 5-stock peer group, OPCH leads on earnings multiple (23.0x) while AVAH leads on capital efficiency (15.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PRVA?

Per PRVA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001759655), Privia Health Group Inc. generated $0 in revenue, $22.9M in net income, and $163.4M in free cash flow against $1.37B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PRVA trading relative to its 50-day, 200-day, and 52-week technical levels?

PRVA last traded at $22.00 (+0.71% on volume of 869,002 shares), positioning the stock +5.36% above its 50-day simple moving average ($20.88) and -2.96% below its 200-day simple moving average ($22.67). Across its 52-week range of $18.92 to $28.82, PRVA sits at the 31.1% percentile with a 14-day RSI of 48.9 (NEUTRAL RANGE) and an implied next-earnings move of ±6.0% ($20.68 to $23.32).

PRVA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is PRVA's 12-month stock price target?

Privia Health Group Inc. (PRVA) carries a 12-month consensus base price target of $21.9 (-0.5% from $22.00), with a bull-case target of $30.26 and a bear-case floor of $17.08.